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ABSTRACT 48 
Objective:  Ovarian cancer is the leading cause of death from gynecologic malignancies in the 49 
Western world.  Fibroblast growth factor receptor (FGFR) signaling has been implicated to play 50 
a role in ovarian tumorigenesis. Mutational activation of one member of this receptor family, 51 
FGFR2, is a frequent event in endometrioid endometrial cancer.   Given the similarities in the 52 
histologic and molecular genetics of ovarian and endometrial cancers, we hypothesized that 53 
activating FGFR2 mutations may occur in a subset of endometrioid ovarian tumors, and possibly 54 
other histotypes.  55 
Methods: Six FGFR2 exons were sequenced in 120 primary ovarian tumors representing the 56 
major histologic subtypes. 57 
Results:  FGFR2 mutation was detected at low frequency in endometrioid (1/46, 2.2%) and 58 
serous (1/41, 2.4%) ovarian cancer.  No mutations were detected in clear cell, mucinous, or 59 
mixed histology tumors or in the ovarian cancer cell lines tested.  Functional characterization of 60 
the FGFR2 mutations confirmed that the mutations detected in ovarian cancer result in receptor 61 
activation.   62 
Conclusions:  Despite the low incidence of FGFR2 mutations in ovarian cancer, the two FGFR2 63 
mutations identified in ovarian tumors (S252W, Y376C) overlap with the oncogenic mutations 64 
previously identified in endometrial tumors, suggesting activated FGFR2 may contribute to 65 
ovarian cancer pathogenesis in a small subset of ovarian tumors.    Despite  66 
the low incidence of FGFR2 mutations in ovarian cancer, anti-FGFR therapies may prove useful 67 
in the small subset of patients whose tumors have activating FGFR2 mutations.   68 
 69 
INTRODUCTION 70 
 4 
The late stage of diagnosis, resistance to chemotherapy, and biologic heterogeneity of 71 
ovarian cancer make it a clinically challenging disease, with an overall 5-year survival rate of 72 
only 46% [1].  The four most common histological subtypes of ovarian cancer are serous (80-73 
85%), endometrioid (10%), clear cell (5%), and mucinous (3%) [2]. The histomorphologic 74 
heterogeneity of ovarian cancers speaks to distinct etiologies and this is supported by the 75 
presence of different underlying genetic alterations.  For example, TP53 mutations are most 76 
common in serous and high-grade endometrioid ovarian carcinomas [3], whereas PTEN, 77 
PIK3CA, and CTNNB1(-catenin) mutations are more common in low-grade endometrioid 78 
ovarian cancer [4-6]. Despite histomorphologic and underlying genetic differences, most 79 
advanced ovarian carcinomas are treated similarly with a standard approach of surgical 80 
cytoreduction followed by carboplatin and paclitaxel combination chemotherapy [7, 8]. 81 
Fibroblast growth factor (FGF) signaling has been previously implicated in ovarian 82 
tumorigenesis. The fibroblast growth factor family includes 18 ligands (FGF1-FGF10 and 83 
FGF16-FGF23) which signal through four transmembrane receptor tyrosine kinases (FGFR1-84 
FGFR4) and their alternatively spliced isoforms [9].  Alternative splicing of the exons that 85 
encode the third immunoglobulin domain of the receptors is the primary determinant of 86 
specificity in FGF/FGFR binding and signaling. These splicing events are highly tissue specific 87 
and give rise to the “b” and “c” receptor isoforms for FGFR1-FGFR3, which possess distinct 88 
ligand specificities [9, 10].  For FGFR2, cells of an epithelial lineage typically only express the 89 
“b” isoform (FGFR2b encoded by exon 8) while mesenchymally derived cells only express the 90 
“c” isoform (FGFR2c utilizing exon 9).  91 
Ovarian carcinomas are thought to arise from cells of the ovarian surface epithelium 92 
(OSE), a layer of poorly committed mesodermally derived epithelial cells surrounding the ovary. 93 
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During the process of malignant transformation, OSE cells become more committed to an 94 
epithelial phenotype, acquiring expression of epithelial-specific markers such as E-cadherin and 95 
CA125 [11].  Normal ovarian surface epithelial cells have been reported to lack the epithelial 96 
FGFR2b isoform and instead express the mesenchymal FGFR2c isoform.  The expression of the 97 
FGFR2c isoform makes OSE unlike most other epithelial cell types and may reflect the 98 
pluripotent nature of the OSE [12, 13].  Interestingly, most epithelial ovarian cancers express 99 
FGFR2b [14], consistent with the increased epithelial differentiation of this tumor type during 100 
malignant transformation. 101 
In the NCI-60 cancer cell line panel [15], the ovarian cancer cell lines are unique with an 102 
almost universal expression of all four FGFRs (FGFR1-FGFR4) and the highest incidence of 103 
detectable expression of FGFR2 mRNA [16]. FGF-stimulated activation of FGFR in epithelial 104 
ovarian cancer cell lines contributes to multiple aspects of the malignant phenotype, including 105 
proliferation, motility, cell survival, and reorganization of the actin cytoskeleton [13]. In vivo, 106 
mRNA and proteins levels of FGF1 (the universal FGF ligand) are associated with poorer overall 107 
survival in patients with high-grade advanced stage serous ovarian tumors [17]. FGF9 is also 108 
implicated as playing a key role in ovarian endometrioid adenocarcinomas carrying defects in the 109 
Wnt/-catenin pathway [18].  110 
Activating mutations in FGFR2 have been reported in a variety of cancer types, including 111 
ovarian carcinoma [19]. As part of the Cancer Genome Project, 26 ovarian tumors were screened 112 
for mutations in FGFR1-4 [20].  A single mutation in FGFR2, G272V, was identified in a serous 113 
ovarian tumor (1 out of 20 serous ovarian tumors screened for an estimated 5% mutation rate).  114 
No mutations were identified in endometrioid, clear cell or mucinous ovarian tumors, although 115 
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only small numbers of these tumor subtypes were evaluated. No mutations were detected in 116 
FGFR1, FGFR3, or FGFR4 in the 26 tumors investigated. 117 
We and others recently identified activating mutations in FGFR2 in endometrial cancer, 118 
primarily in the endometrioid histologic subtype [21, 22]. Interestingly, ovarian cancer and 119 
endometrial cancer display similarities both histologically and at the molecular genetics level. 120 
Endometrioid ovarian carcinoma bears close histological resemblance to endometrioid 121 
carcinoma of the endometrium.  Endometrioid cancers of the ovary and endometrium share 122 
mutations in PTEN, PIK3CA, and CTNNB1 (-catenin) [4-6, 23-25].   123 
Previous reports implicating FGF signaling in ovarian tumorigenesis coupled with the 124 
fact endometrioid ovarian cancer and endometrioid endometrial cancer share a number of cancer 125 
associated molecular lesions led us to hypothesize that FGFR2 mutations similar to those seen in 126 
endometrial cancers may occur in a subset of ovarian neoplasms.   127 
 128 
MATERIALS AND METHODS 129 
Clinical specimens and cell lines 130 
120 fresh frozen ovarian tumor samples from multiple institutions were investigated, including 131 
46 endometrioid, 41 serous, 14 mucinous, 12 clear cell, and 7 mixed histology ovarian tumors.  132 
Ovarian tumor samples were obtained from Ian Campbell at the Peter MacCallum Cancer 133 
Institute (26 endometrioid, 32 serous, 10 mucinous, 5 clear cell, and 3 mixed histology ovarian 134 
tumors), Michael Birrer at the National Cancer Institute (5 endometrioid, 9 serous, 4 mucinous, 7 135 
clear cell, and 4 mixed histology), and Paul Goodfellow at Washington University (15 136 
endometrioid tumors). The majority of specimens used in this study contained >70% tumor 137 
epithelial cells, as determined by H&E staining of multiple sections. For a subset of tumors 138 
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microdissection of frozen sections was required to enrich for neoplastic cells. All samples were 139 
deidentified and the study approved by the Western Institutional Review Board (WIRB).  140 
Ovarian tumor DNA provided by Dr Ian Campbell underwent whole genome amplification 141 
(WGA) using the Repli-G Phi-mediated amplification system (Qiagen, Hilden, Germany), as 142 
previously described [26]. Six ovarian cancer cell lines (CAOV3, ES-2, OVCAR-3, SKOV3, 143 
SWS-26, TOV-21G) were also sequenced for FGFR2 mutations.  144 
 145 
Detection of FGFR2 mutations 146 
Ovarian tumor samples were screened for FGFR2 mutations in exons 7, 8, 9, 10, 13, and 15, as 147 
previously described [21].  Primers pairs were designed to amplify from intronic sequences 148 
flanking the target exon to include splice sites and the regions proximal to exon 9 previously 149 
associated with disrupted FGFR2 splicing due to Alu insertion [27, 28].  All sequencing was 150 
performed at the Translational Genomics Research Institute Sequencing Core.  151 
 152 
BaF3 proliferation assays 153 
The S252W and Y376C mutations were introduced to the pEF1.FGFR2b.IRES.neo plasmid 154 
(NM_022970.3) using the Quikchange XL Site Directed Mutagenesis Kit (Stratagene) according 155 
to manufacturer’s instructions. Mutagenesis primers were designed to introduce a missense 156 
mutation to encode for the desired mutation in FGFR2 (indicated in bold) and a silent mutation 157 
for diagnostic restriction digestion screening of clones (indicated by underline). Site-directed 158 
mutagenesis primer sequences were as follows: FGFR2 S252W Forward: 5’-159 
GTTGTGGAGCGCTGGCCTCACCGGCC-3’; FGFR2 S252W Reverse: 5’-160 
GGCCGGTGAGGCCAGCGCTCCACAAC-3’; FGFR2 Y376C Forward:  5’–161 
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GATTACAGCTTCCCCAGACTGCCTCGAGATAGCCAT-3’; FGFR2 Y376C Reverse:  5’–162 
ATGGCTATCTCGAGGCAGTCTGGGGAAGCTGTAATC-3’.  After restriction enzyme 163 
screening, the entire FGFR2 coding region was sequenced to confirm the presence of the 164 
mutation of interest and to ensure that no other mutations were introduced during the 165 
mutagenesis process.  166 
The IL-3 dependent murine pro B BaF3 cell line was transduced with empty vector, 167 
wildtype FGFR2b and mutant FGFR2b using Amaxa nucleofection, according to the 168 
manufacturer’s instructions.    Transduced cells were stably selected with 1.2 mg/mL Geneticin 169 
in the presence of 5 ng/ml IL-3 for 14 days, and then maintained under selection in RPMI 170 
supplemented with 10% FBS, 50 nM beta-mercaptoethanol, 100 U/mL penicillin, 100 g/mL 171 
streptomycin sulfate, 1.2 mg/mL Geneticin and 5 ng/mL murine IL-3 (R&D Systems).  For the 172 
proliferation assays, cells were washed in PBS to remove IL-3, and plated at 1 x 10
4
 cells per 173 
well in triplicate in a 96 well plate in IL-3 free media containing 1 nM FGF7 and 5 g/mL 174 
heparin. Cells had a 50% volume media change on day 3 to provide fresh FGF ligand. On day 175 
five, bioluminescent measurement of ATP was assessed as an indicator of cell number using the 176 
ViaLight Plus Cell Proliferation/Cytotoxity Kit (Lonza Rockland, Inc.), according to the 177 
manufacturer’s instructions. Experiments were performed twice in each of two independent sets 178 
of stable cell lines, with triplicate wells measured for each assay.   179 
 180 
RESULTS AND DISCUSSION 181 
To characterize the spectrum and frequency of FGFR2 mutations across the histological 182 
subtypes of ovarian cancer, 120 ovarian tumors, including 46 endometrioid, 41 serous, 14 183 
mucinous, 12 clear cell, and 7 mixed histology ovarian tumors, were screened for mutations in 184 
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FGFR2.  Direct sequencing was undertaken for exons 7, 8, 9, 10, 13, and 15.  These six exons 185 
include >95% of mutations identified in endometrial cancers ([22] and our unpublished results). 186 
Furthermore, the majority of germline mutations in the FGFR gene family associated with 187 
skeletal and craniosynostosis syndromes occur within these exons. Alternative splicing of 188 
FGFR2 exon 8 and exon 9 occurs in a tissue specific fashion, where cells of an epithelial lineage 189 
usually only express the ‘b’ isoform encoded by exon 8 (FGFR2b) and mesenchymally derived 190 
cells only express the ‘c’ isoform utilizing exon 9 (FGFR2c). The distinct ligand specificities of 191 
these receptor isoforms, coupled with tissue-specific ligand expression, mediate normal paracrine 192 
epithelial-mesenchymal signaling.  Although no activating mutations in exon 8 have been 193 
identified in endometrial cancer to date, a large number of activating mutations in exon 9 of 194 
FGFR2 in craniosynostosis and skeletal dysplasia syndromes have been identified.  Given that 195 
normal ovarian surface epithelium express FGFR2c (utilizing exon 9) and a majority of ovarian 196 
carcinomas express FGFR2b (utilizing exon 8) [11-13], we screened both exon 8 and exon 9 for 197 
mutations.   198 
Mutations in FGFR2 were identified in 1/46 (2.2%) endometrioid and 1/41 (2.4%) serous 199 
ovarian tumors.  Sequencing revealed the normal DNA was wildtype confirming the mutations 200 
were somatic in origin. No mutations were seen in mucinous, clear cell, or mixed histology 201 
ovarian tumors.  In addition, no mutations were detected in FGFR2 in the six ovarian cancer cell 202 
lines tested (CAOV3, ES-2, OVCAR-3, SKOV3, SWS-26, TOV-21G).   203 
Both of the mutations identified in ovarian tumor samples have been previously reported 204 
in endometrial cancer [21].  S252W, the most common mutation observed in endometrioid 205 
endometrial cancer [21], was identified here in a grade 2, stage III, endometrioid ovarian tumor 206 
and the Y376C mutation was identified in a grade 3, stage III, serous ovarian tumor.  A novel 207 
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G272V mutation in FGFR2 has been previously reported in a single serous ovarian tumor [20]. 208 
The functional consequence of this mutation is unknown. However, the absence of the G272V 209 
mutation in our cohort suggests that this is not a hotspot mutation for FGFR2.  Furthermore, in 210 
contrast to the known causative role for S252W and Y376C mutations in FGFR2 in Apert and 211 
Beare-Stevenson syndromes, respectively (reviewed in [29]), the absence of the G272V mutation 212 
in the germline in FGFR2 mutation driven skeletal disorders (Apert, Crouzon, Pfeiffer, Beare-213 
Stevenson, Jackson-Weiss syndromes) suggests it may be a passenger mutation, though 214 
ultimately this needs to be functionally validated. Altered splicing of FGFR2 due to Alu 215 
insertions has been described as an alternative mechanism of FGFR2 activation in a small subset 216 
of patients with Apert syndrome [27, 28], however similar alterations were not identified in any 217 
of the ovarian tumors analyzed.   218 
S252W is located in the highly conserved linker region between the second and third 219 
immunoglobulin-like domains in the extracellular domain of the receptor. Extensive structural 220 
and biological studies evaluating the causative role of the S252W mutation in the 221 
craniosynostosis and limb pathologies of Apert syndrome have shown that the mutation results in 222 
activation of the FGFR2b and FGFR2c receptors by two mechanisms.  First, the mutation 223 
increases the binding affinity of the receptor isoforms for their cognate ligands.  The S252W 224 
mutant receptor also violates ligand binding specificity: e.g. the “c” isoform can now bind “b” 225 
isoform specific ligands, resulting in autocrine receptor activation [30-32]. Normal ovarian 226 
surface epithelial cells are unique in that they are the only epithelial tissue identified to date that 227 
express FGFR2c and FGF7, members of the FGF signaling family that are typically expressed in 228 
mesenchymally derived tissues [33]. Interestingly, the majority of ovarian carcinomas express 229 
FGFR2b, and FGF7 has been shown to stimulate DNA synthesis in ovarian cancer cell lines 230 
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expressing FGFR2b, suggesting the establishment of an autocrine loop [14]. Whether these cells 231 
have maintained expression of FGFR2c or have undergone an isoform switch from FGFR2c to 232 
FGFR2b is currently unknown. Functional studies have shown that a neutralizing antibody to 233 
FGF7 can partially inhibit DNA synthesis in the FGFR2b-expressing ovarian carcinoma cell line, 234 
41 M [14], suggesting that this isoform switching may play a role in ovarian tumorigenesis rather 235 
than just being a “passenger” event that accompanies the epithelial differentiation of this tumor 236 
type during malignant transformation. Although it is unknown whether the ovarian tumor with 237 
the S252W mutation in FGFR2 identified in this study predominantly expresses the “b” or the 238 
“c” isoform of FGFR2, it is tempting to speculate that this tumor expresses the “c” isoform only.  239 
The S252W mutation would then phenotypically mimic the previously identified isoform 240 
switching, thereby allowing the autocrine activation of FGFR2c by FGF7 in OSE cells. The 241 
identification of the pathogenic S252W mutation in this single tumor would in turn suggest that 242 
the isoform switching previously observed in ovarian tumors plays a role in the pathogenesis of 243 
these tumors. The low rate of activating mutations in FGFR2 identified to date may reflect that in 244 
this tissue type FGFR2 is already activated in a ligand dependent manner by isoform switching, 245 
and may not require additional mutational activation.  246 
Y376C is located in the juxtamembrane domain of FGFR2.  Studies investigating the 247 
causative role of this mutation in Beare-Stevenson syndrome have proposed that the introduction 248 
of an unpaired cysteine by this mutation results in receptor activation through formation of either 249 
intermolecular bonds (resulting in covalent dimerization between mutant receptors) or 250 
intramolecular bonds (resulting in interactions with two cysteines in the transmembrane domain) 251 
[34]. Given that the S252W mutation results in ligand-dependent receptor activation, we 252 
undertook studies to determine the ligand-dependency of the Y376C mutation. The homologous 253 
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Y372C mutation in FGFR1 results in ligand independent activation of an osteocalcin FGF 254 
response element promoter-luciferase reporter in the osteogenic MC3T3 cell line [35], 255 
presumably by the formation of intermolecular disulfide bonds [36]. The homologous Y373C 256 
mutation in FGFR3c has been shown to result in receptor dimerization, but predominantly ligand 257 
dependent activation of the MAPK pathway in HEK293 cells and L8 myoblasts [37]. We 258 
assessed mitogen dependence using the BaF3 cell assay. BaF3 cells do not express endogenous 259 
FGF ligands or FGFRs and are IL-3 dependent.  Introduction and activation of FGFRs has been 260 
shown to substitute for IL-3 to promote cell proliferation [38]. As shown in Figure 1A, the 261 
Y376C mutation results in ligand independent receptor activation, as evidenced by BaF3 262 
proliferation in the absence of FGF ligand. Stimulation with FGF7 resulted in increased 263 
proliferation in the Y376C FGFR2b BaF3 cells compared to wildtype FGFR2b (Figure 1B), 264 
demonstrating the mutant receptor can be further activated by the addition of ligand. This is in 265 
contrast to the S252W mutation that does not lead to BaF3 proliferation in the absence of ligand, 266 
similar to wildtype FGFR2b (Figure 1A).  The S252W mutation does lead to increased BaF3 267 
proliferation in response to its cognate ligand (Figure 1B), as previously reported [30]. We 268 
should note that these functional studies were carried out using the “b” isoform of FGFR2 as the 269 
effect of the Y376C mutation on receptor dimerization is independent of the “b” or “c” isoform 270 
on which it arises.  271 
In conclusion, we identified an S252W mutation in a single endometrioid ovarian 272 
carcinoma and a Y376C mutation in a single serous ovarian tumor. The S252W mutation 273 
violates the ligand binding specificity of FGFR2b and FGFR2c and phenotypically mimics the 274 
occurrence of FGFR2 isoform switching previously observed in ovarian cancer whereas the 275 
Y376C mutation results in constitutive receptor activation. In the era of personalized medicine, 276 
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we anticipate that hotspot FGFR2 mutations, including S252W and Y376C, will be incorporated 277 
into a multi-gene panel to profile rare somatic mutations, allowing identification of FGFR2 278 
mutant tumors even within cancer types with low mutation frequency. Additional studies are 279 
needed to determine the pathogenic consequences and therapeutic potential of targeting aberrant 280 
activation of FGFR2 due to mutation or isoform switching in ovarian cancer.  However, the 281 
identification of activating mutations in FGFR2 in ovarian tumors that overlap with the known 282 
oncogenic mutations in FGFR2 in endometrial cancer, and the selective sensitivity of FGFR2 283 
mutant endometrial cancer cell lines to FGFR inhibition [39], raises the possibility that Together 284 
these data raise the possibility that inhibition of FGFR2 by either small molecule kinase 285 
inhibitors or extracellular blocking antibodiesFGFR inhibitors may be beneficial in the small 286 
subset of women whose ovarian tumors possesshave activating FGFR2 mutations. Furthermore, 287 
given that at least one identified mutation functionally mimics FGFR2 isoform switching, there 288 
is potential that , as well as inthis may extend to the yet undefined subset of women whose 289 
tumorscases that have undergone FGFR2 isoform switching. 290 
 291 
292 
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Figure Legends: 428 
 429 
Figure 1.   Effects of S252W and Y376C mutations on FGFR2b activity in BaF3 cells  (A) 430 
Proliferation of BaF3 cells expressing empty vector (EV), wildtype FGFR2b, or mutant (S252W, 431 
Y376C) FGFR2b in the absence of FGF ligand.  (B) Proliferation of BaF3 cells expressing 432 
empty vector (EV), wildtype FGFR2b, or mutant (S252W, Y376C) FGFR2b in response to 433 
FGF7, a cognate FGFR2b ligand.  434 
 435 
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